Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Omeprazole on XS004 (Dasynoc) in Healthy Adults
NCT05433896Phase 1Completed
- Sponsor
- Xspray Pharma
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dasynoc in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Xspray Pharma. Primary endpoints: Maximum Observed Plasma Concentration at Day 6, Area Under the Plasma Concentration-Time Curve from Zero to 24h and 1 more. Started Nov 2020; status: completed.
02
Drugs
Dasynoc
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05433896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433896.